Prevalence and titers of yellow fever virus neutralizing antibodies in previously vaccinated adults
Prevalence and titers of yellow fever virus neutralizing antibodies in previously vaccinated adults
复制标题
DOI：
10.1590/s1678-9946201759002
复制
发表时间：
2017-01-01
期刊：
影响因子：
--
通讯作者：
Sartori, Ana Marli Christovam
中科院分区：
文献类型：
--
作者：
Miyaji, Karina Takesaki;Avelino-Silva, Vivian Iida;Sartori, Ana Marli Christovam
简介：世界卫生组织（WHO）根据对健康成人抗体持续存在的研究，建议接种一剂黄热病疫苗。我们评估了年龄≥ 60岁的既往接种过疫苗的人群与年轻人相比，YF病毒中和抗体的流行率和滴度。我们还评估了接种一剂疫苗的参与者中抗体滴度与接种后时间之间的相关性，以及在过去10年内或之前接种疫苗的参与者中的血清阳性率。方法：既往接种过疫苗的健康人，年龄≥ 18岁。通过50%空斑减少中和试验测定YF病毒中和抗体滴度。结果：46名年龄≥ 60岁的患者和48名年龄18 - 59岁的患者入组。两组间YF病毒中和抗体的流行率无显著差异（p = 0.263）。然而，老年人的滴度显著较低（p = 0.022）。YF病毒中和抗体滴度与接种后时间无相关性。在过去10年内或之前接种疫苗的参与者之间的血清阳性率没有显着差异。结论：两组间观察到的YF病毒中和抗体滴度差异的临床相关性尚不清楚。
Introduction: The World Health Organization (WHO) recommends one single dose of the Yellow Fever (YF) vaccine based on studies of antibody persistency in healthy adults. We assessed the prevalence and titers of YF virus neutralizing antibodies in previously vaccinated persons aged >= 60 years, in comparison to younger adults. We also evaluated the correlation between antibody titers and the time since vaccination among participants who received one vaccine dose, and the seropositivity among participants vaccinated prior to or within the past 10 years. Methods: previously vaccinated healthy persons aged >= 18 years were included. YF virus neutralizing antibody titers were determined by means of the 50% Plaque Reduction Neutralization Test. Results: 46 persons aged >= 60 years and 48 persons aged 18 to 59 years were enrolled. There was no significant difference in the prevalence of YF virus neutralizing antibodies between the two groups (p = 0.263). However, titers were significantly lower in the elderly (p = 0.022). There was no correlation between YF virus neutralizing antibody titers and the time since vaccination. There was no significant difference in seropositivity among participants vaccinated prior to or within the past 10 years. Conclusions: the clinical relevance of the observed difference in YF virus neutralizing antibody titers between the two groups is not clear.